Cellid Crashes After-Hours on Phase 3 Failure...Shaperon Dives 25%[K-bio pulse]

In the biopharmaceutical sector on Friday, Cellid s stock surged on expectations for its vaccine clinical trial results, but the shares plunged by the daily limit in after-hours trading followi...